Brief: Sequana Medical: FDA Clearance Of IND Application For DSR 2.0

Sequana Medical NV

02/05/2023 06:05

May 2 (Reuters) - Sequana Medical NV  SEQUA.BR :
    * SEQUANA MEDICAL ANNOUNCES FDA CLEARANCE OF IND APPLICATION
FOR
DSR® 2.0 FOR TREATMENT OF CONGESTIVE HEART FAILURE
    * MOJAVE STUDY ON TRACK TO START IN Q2 2023 AS PLANNED, WITH
INITIAL DATA BY YEAR-END
    * DSR WELL POSITIONED AS DISEASE-MODIFYING HEART FAILURE
THERAPY
    * RANDOMIZED, CONTROLLED STUDY IN US SEEKING TO CONFIRM
STRONG
EFFICACY DATA SEEN IN RED DESERT AND SAHARA STUDIES

Source text for Eikon:  ID:nGNE2rRzRn 
Further company coverage:  SEQUA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))